Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there is an emerging adverse event as facial erythema. A twenty-seven-year-old female patient developed erythema and desquamation on the face and neck after dupilumab administration. She had AD on her arms, legs, and trunk before the treatment but there was no atopic clinical feature in her face and neck. With the treatment of dupilumab, her skin lesions of the body have improved from the beginning of the treatment. In the patch test, including dupilumab, there was no specific finding other than the 1+ response to neomycin on day 2. In the intradermal test to dupilumab, a positive result was observed 15 min later, but negative both days 1 and 2. The blood examination showed an elevation of both ANA as 1:80 and anti-phospholipid antibodies (Anti-cardiolipin IgM, IgG, and Anti- beta 2 GPI IgG). She was diagnosed with Systemic lupus erythematosus (SLE) based on diagnostic criteria by a rheumatologist. Dupilumab is an emerging therapeutic agent for AD, and treatment cases are increasing in Korea. However, there are several adverse events during the treatment of dupilumab. Herein, we report the unexpected adverse event during the treatment of dupilumab in SLE patients.

中文翻译：

---

SLE 患者使用 dupilumab 治疗后的面部红斑。

Dupilumab 是一种受体拮抗剂，可与白介素 4 受体的 α 亚基结合。通过与其结合，dupilumab 可抑制 IL-4 和 IL-13（代表性的 Th2 生物标志物）的信号传导。最近，除了对特应性皮炎（AD）的治疗效果外，还出现了面部红斑等不良事件。一名 27 岁的女性患者在使用 dupilumab 后面部和颈部出现红斑和脱屑。治疗前她的手臂、腿和躯干有 AD，但她的面部和颈部没有特应性临床特征。通过dupilumab的治疗，她身体的皮肤病变从治疗开始就有所改善。在包括 dupilumab 在内的斑贴试验中，除了第 2 天对新霉素的 1+ 反应外，没有任何特异性发现。在对 dupilumab 的皮内试验中，15 分钟后观察到阳性结果，但第 1 天和第 2 天均为阴性。血液检查显示 ANA 和抗磷脂抗体（抗心磷脂 IgM、IgG 和抗 β 2 GPI IgG）升高为 1:80 ）。根据风湿病学家的诊断标准，她被诊断为系统性红斑狼疮 (SLE)。Dupilumab 是一种新兴的 AD 治疗药物，在韩国治疗病例正在增加。然而，在 dupilumab 的治疗过程中有几个不良事件。在此，我们报告了 SLE 患者在 dupilumab 治疗期间的意外不良事件。根据风湿病学家的诊断标准，她被诊断为系统性红斑狼疮 (SLE)。Dupilumab 是一种新兴的 AD 治疗药物，在韩国治疗病例正在增加。然而，在 dupilumab 的治疗过程中有几个不良事件。在此，我们报告了 SLE 患者在 dupilumab 治疗期间的意外不良事件。根据风湿病学家的诊断标准，她被诊断为系统性红斑狼疮 (SLE)。Dupilumab 是一种新兴的 AD 治疗药物，在韩国治疗病例正在增加。然而，在 dupilumab 的治疗过程中有几个不良事件。在此，我们报告了 SLE 患者在 dupilumab 治疗期间的意外不良事件。